专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US07514447B2 Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors 有权
公开(公告)号：US07514447B2
公开(公告)日：2009-04-07
申请号：US11535455
申请日：2006-09-26
申请人： Valentina Molteni , Xiaolin Li , Donatella Chianelli , Jon Loren , Juliet Nabakka , Xiadong Liu , Shifeng Pan , Yi Liu , Donald S. Karanewsky , Pascal Furet , Vito Guagnano , Shuli You
发明人： Valentina Molteni , Xiaolin Li , Donatella Chianelli , Jon Loren , Juliet Nabakka , Xiadong Liu , Shifeng Pan , Yi Liu , Donald S. Karanewsky , Pascal Furet , Vito Guagnano , Shuli You
IPC分类号： C07D239/42 , C07D403/10 , C07D403/14 , A61K31/505 , A61K31/506 , A61P35/00
CPC分类号： C07D403/04 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/10
摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

32. 发明申请

US20090087493A1 Supramolecular Functionalization of Graphitic Nanoparticles for Drug Delivery 有权
标题翻译：石墨纳米粒子用于药物递送的超分子官能化
公开(公告)号：US20090087493A1
公开(公告)日：2009-04-02
申请号：US12178891
申请日：2008-07-24
申请人： Hongjie Dai , Zhuang Liu , Xiaolin Li , Xiaoming Sun
发明人： Hongjie Dai , Zhuang Liu , Xiaolin Li , Xiaoming Sun
IPC分类号： A61K9/16 , C12N5/00 , A61K39/395
CPC分类号： A61K47/48215 , A61K9/0092 , A61K31/337 , A61K31/704 , A61K38/16 , A61K39/395 , A61K47/62 , A61K47/68 , A61K47/6925 , A61K47/6929 , A61K47/6949 , B82Y5/00 , Y10T428/2982
摘要： Disclosed are nanoparticles, such as carbon nanotubes or other materials having extended aromatic surfaces (e.g., graphene sheet or nanotube), which are used to deliver active agents such as drugs, labels or dyes (termed for convenience a “drug”) to the interior of cells. The nanoparticles are functionalized by a hydrophilic polymer to render them stable in suspension. This molecule may be covalently attached to the nanoparticle, or may be adsorbed thereto as an amphiphilic molecule. The nanoparticles are coupled to the drug through supramolecular bonding i.e., binding to the exterior of the nanoparticle through π-stacking. The drug may also be covalently bonded to the hydrophilic polymer, which is coupled to the nanoparticle through supramolecular bonding. The drug is therefore capable of release in the cell exterior. The drug is more rapidly released at lower pH, as found e.g., in tumor cells. The drug-coupled, functionalized nanoparticles may also be targeted to specific cells through modification of the hydrophilic polymer, e.g., by adding an RGD peptide, or an antibody, which is targeted to cells expressing integrins, or an antibody directed to a cell surface marker. The drug may also be linked to a branched chain hydrophilic polymer, so that each polymer molecule carries more than one drug bound by a cleavable linker.
摘要翻译：公开了纳米颗粒，例如碳纳米管或具有延伸的芳族表面的其它材料（例如，石墨烯片或纳米管），其用于将活性剂如药物，标记或染料（为方便起见称为“药物”）递送到内部的细胞。纳米颗粒由亲水性聚合物官能化，使其在悬浮液中稳定。该分子可以共价连接到纳米颗粒上，或者可以作为两亲分子被吸附。纳米颗粒通过超分子键合与药物偶联，即通过π-堆叠与纳米颗粒的外部结合。该药物也可以与亲水性聚合物共价键合，亲水性聚合物通过超分子键合与纳米颗粒偶联。因此，该药物能够在细胞外释放。药物在较低的pH下更快速释放，例如在肿瘤细胞中发现。药物偶联的官能化纳米颗粒也可以通过改性亲水性聚合物来靶向特定细胞，例如通过添加靶向表达整联蛋白的细胞的RGD肽或抗体或针对细胞表面标记的抗体。药物也可以连接到支链亲水性聚合物，使得每个聚合物分子携带多于一种可切割接头结合的药物。

33. 发明申请

US20090062260A1 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS 审中-公开
标题翻译：作为LXR调节剂的化合物和组合物
公开(公告)号：US20090062260A1
公开(公告)日：2009-03-05
申请号：US12092065
申请日：2006-11-14
申请人： Valentina Molteni , David A. Ellis , Juliet Nabakka , Donatella Chianelli , Enrique Saez , Xiaolin Li , Sylvie Chamoin , Hans-Jorg Roth
发明人： Valentina Molteni , David A. Ellis , Juliet Nabakka , Donatella Chianelli , Enrique Saez , Xiaolin Li , Sylvie Chamoin , Hans-Jorg Roth
IPC分类号： A61K31/395 , C07D401/02 , A61K31/454 , C07D211/30 , A61K31/445 , A61P9/00 , A61P3/10 , A61P29/00 , A61P25/28 , A61K31/4545 , A61K31/496 , C07D401/14 , A61K31/551
CPC分类号： C07D401/10
摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
摘要翻译：本发明提供化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与肝脏X受体（LXR）活性相关的疾病或病症的方法。

34. 发明申请

US20070149538A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors 有权
标题翻译：含二芳基胺的化合物和组合物，以及它们作为C-Kit受体的调节剂的用途
公开(公告)号：US20070149538A1
公开(公告)日：2007-06-28
申请号：US11535455
申请日：2006-09-26
申请人： Valentina Molteni , Xiaolin Li , Donatella Chianelli , Jon Loren , Shuli You , Juliet Nabakka , Xiadong Liu , Shifeng Pan , Yi Liu , Donald Karanewsky , Pascal Furet , Vito Guagnano
发明人： Valentina Molteni , Xiaolin Li , Donatella Chianelli , Jon Loren , Shuli You , Juliet Nabakka , Xiadong Liu , Shifeng Pan , Yi Liu , Donald Karanewsky , Pascal Furet , Vito Guagnano
IPC分类号： A61K31/496 , C07D403/02
CPC分类号： C07D403/04 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/10
摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
摘要翻译：本文描述的是包括二芳基胺结构特征的化合物。本文还描述了制备这种化合物的方法，使用这些化合物调节c-kit受体的活性的方法，以及包含这些化合物的药物组合物和药物。本文还描述了使用这些化合物，药物组合物和药物来治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或病症的方法。

35. 发明授权

US09822423B2 Method for producing silicon steel normalizing substrate 有权
公开(公告)号：US09822423B2
公开(公告)日：2017-11-21
申请号：US14379777
申请日：2012-03-26
申请人： Hongxu Hei , Bo Wang , Shishu Xie , Xiandong Liu , Guohua Yang , Yongjie Yang , Aihua Ma , Xiaolin Li , Liang Zou , Huawei Zhang
发明人： Hongxu Hei , Bo Wang , Shishu Xie , Xiandong Liu , Guohua Yang , Yongjie Yang , Aihua Ma , Xiaolin Li , Liang Zou , Huawei Zhang
IPC分类号： C21D1/00 , C21D8/12 , C21D1/76 , C21D6/00 , C21D1/34 , H01F41/00 , C21D9/46 , C21D1/28
CPC分类号： C21D8/1261 , C21D1/28 , C21D1/34 , C21D1/76 , C21D6/008 , C21D8/1222 , C21D8/1233 , C21D9/46 , H01F41/00
摘要： A method for producing a silicon steel normalizing substrate comprises: steelmaking, hot rolling and normalizing steps. The normalizing step uses a normalizing furnace having a nonoxidizing heating furnace section. The nonoxidizing heating furnace section comprises more than 3 furnace zones. An energy investment ratio of the furnace zones used in the nonoxidizing heating furnace section is adjusted, so as to control an excess coefficient α of the nonoxidizing heating furnace section to be within a range of 0.8≦α

36. 发明授权

US09199981B2 Compounds and compositions as C-kit kinase inhibitors 有权
标题翻译：化合物和组合物作为C-kit激酶抑制剂
公开(公告)号：US09199981B2
公开(公告)日：2015-12-01
申请号：US13595575
申请日：2012-08-27
申请人： Vince Yeh , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Bao Nguyen , Hank Michael James Petrassi
发明人： Vince Yeh , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Bao Nguyen , Hank Michael James Petrassi
IPC分类号： C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , C07D471/04
CPC分类号： C07D471/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
摘要翻译：本发明提供了可用作蛋白激酶抑制剂的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调激酶活性相关的病症的方法。在一些实施方案中，本发明提供了使用这些化合物治疗，改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα，PDGFR＆bgr））激酶的异常活化的疾病或病症的方法。

37. 发明授权

US09047462B2 Computer account management system and realizing method thereof 有权
标题翻译：计算机帐户管理系统及其实现方法
公开(公告)号：US09047462B2
公开(公告)日：2015-06-02
申请号：US14342121
申请日：2012-04-18
申请人： Zhiwei Xu , Guojie Li , Xiaolin Li , Yi Xie , Qiang Yue
发明人： Zhiwei Xu , Guojie Li , Xiaolin Li , Yi Xie , Qiang Yue
IPC分类号： G06F21/45 , H04L9/32 , H04L29/06
CPC分类号： G06F21/45 , H04L9/3263 , H04L63/0815
摘要： A computer account management system includes: an account management subsystem; an information asset management subsystem; an authentication (integrated) subsystem; a service (integrated) subsystem; and an account portal subsystem; wherein the account management subsystem manages information of physical accounts and logical account numbers; wherein the information asset management subsystem manages data information resources generated by network activities of physical account information; wherein the authentication subsystem provides an authentication integrated interface to the physical account numbers; wherein the service subsystem is a customizable interface which is open to internet or local network; wherein the account portal provides interfaces and tools of login, service list management of services subscribed or bought by the account, account information management and information asset management. The computer account management system is not bundled with services, seamlessly integrated with the user information asset and is lifetime-valid. The system can be used in account management of the internet.
摘要翻译：计算机帐户管理系统包括：帐户管理子系统; 信息资产管理子系统; 一个认证（集成）子系统; 一个服务（集成）子系统; 和帐户门户子系统; 其中所述帐户管理子系统管理物理账户和逻辑账号的信息; 其中信息资产管理子系统管理由物理账户信息的网络活动产生的数据信息资源; 其中所述认证子系统向所述实体帐号提供认证集成接口; 其中所述服务子系统是对互联网或本地网络开放的可定制接口; 其中帐户门户提供登录的接口和工具，帐户订阅或购买的服务的服务列表管理，帐户信息管理和信息资产管理。计算机帐户管理系统不与服务捆绑，与用户信息资产无缝集成，具有终身有效性。该系统可用于互联网的帐户管理。

38. 发明授权

US08753772B2 Graphene-sulfur nanocomposites for rechargeable lithium-sulfur battery electrodes 有权
标题翻译：用于可再充电锂硫电池电极的石墨烯 - 硫磺纳米复合材料
公开(公告)号：US08753772B2
公开(公告)日：2014-06-17
申请号：US13023241
申请日：2011-02-08
申请人： Jun Liu , John P. Lemmon , Zhenguo Yang , Yuliang Cao , Xiaolin Li
发明人： Jun Liu , John P. Lemmon , Zhenguo Yang , Yuliang Cao , Xiaolin Li
IPC分类号： H01M4/583 , H01M4/60 , H01M4/88 , B82Y40/00 , B82Y30/00
CPC分类号： H01M4/049 , B82Y30/00 , H01M4/136 , H01M4/1397 , H01M4/5815 , H01M4/623 , H01M10/052 , Y02E60/122 , Y10S977/734 , Y10S977/773 , Y10S977/84
摘要： Rechargeable lithium-sulfur batteries having a cathode that includes a graphene-sulfur nanocomposite can exhibit improved characteristics. The graphene-sulfur nanocomposite can be characterized by graphene sheets with particles of sulfur adsorbed to the graphene sheets. The sulfur particles have an average diameter less than 50 nm.
摘要翻译：具有包含石墨烯 - 硫磺纳米复合材料的阴极的可充电锂 - 硫电池可以表现出改进的特性。石墨烯 - 硫磺纳米复合材料可以用石墨烯片表征，其中硫的颗粒吸附到石墨烯片上。硫颗粒的平均直径小于50nm。

39. 发明申请

US20140134132A1 CYCLIC PEPTIDES AND USE AS MEDICINES 有权
标题翻译：循环肽和用作药物
公开(公告)号：US20140134132A1
公开(公告)日：2014-05-15
申请号：US14037644
申请日：2013-09-26
申请人： Jiping Fu , Subramanian Karur , Xiaolin Li , Peichao Lu , Wosenu Mergo , Alexey Rivkin , Zachary Kevin Sweeney , Meiliana Tjandra , Andrew Weiss , Aregahegn Yifru
发明人： Jiping Fu , Subramanian Karur , Xiaolin Li , Peichao Lu , Wosenu Mergo , Alexey Rivkin , Zachary Kevin Sweeney , Meiliana Tjandra , Andrew Weiss , Aregahegn Yifru
IPC分类号： A61K38/12 , A61K45/06 , C07K7/64
CPC分类号： A61K38/13 , A61K38/12 , A61K45/06 , C07K7/64 , C07K7/645 , A61K2300/00
摘要： The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.
摘要翻译：本发明提供式I化合物; 或其药学上可接受的盐，其中本文定义的变量R1，R2，R3，R4，R5和AB是非免疫抑制性亲环蛋白结合的mPTP阻断剂，因此可用于预防或治疗疾病或疾病如HCV感染，中风，多发性硬化，HBV感染，HPV感染，哮喘，癌症，肌营养不良，败血症，缺血/再灌注损伤和心力衰竭。

40. 发明申请

US20130345220A1 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS 审中-公开
公开(公告)号：US20130345220A1
公开(公告)日：2013-12-26
申请号：US14013482
申请日：2013-08-29
申请人： Valentina MOLTENI , Xiaolin Li , Juliet Nabakka , David Archer Ellis , Beth Anaclerio , Enrique Saez , John Wityak
发明人： Valentina MOLTENI , Xiaolin Li , Juliet Nabakka , David Archer Ellis , Beth Anaclerio , Enrique Saez , John Wityak
IPC分类号： C07D285/12 , C07D417/12 , C07D417/04 , A61K45/06 , A61K31/506 , C07D417/14 , A61K31/444 , A61K31/433 , A61K31/4439
CPC分类号： C07D285/12 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K45/06 , C07D417/04 , C07D417/12 , C07D417/14
摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式